LivingGLP1
Study S000204

An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy

Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT04431713
Acronym
MSA
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
NONE
Status
COMPLETED
Enrollment
50
Start
2020-09-16
Primary completion
2024-03-22
Lead sponsor
University College, London
Conditions
Multiple System Atrophy
Interventions
DRUG:Exenatide Pen Injector [Bydureon]
Results posted
TRUE
Individual participant data sharing
NO
Secondary identifiers
EUDRACT_NUMBER:2020-000122-26

Registered primary outcomes

  • Change in UMSARS Score (Parts I+II) From Baseline [Baseline and 48 weeks]

Linked records (16)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0020031Mild-to-moderate depressive symptoms impact on self-reported outcome measures in clinical trials for neurodegenerative diseases.
Girges C, Clinical trials (London, England)
2026Other trialPMID 41321006DOIcites ClinicalTrials.gov:NCT04431713; registry reference DERIVED:41321006
R0024236Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.
Athauda D, JAMA neurology
2019Randomized trialPMID 30640362DOIregistry reference BACKGROUND:30640362
R0021473What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.
Athauda D, Journal of Parkinson's disease
2018Randomized trialPMID 29843254DOIregistry reference BACKGROUND:29843254
R0016373Insulin resistance and exendin-4 treatment for multiple system atrophy.
Bassil F, Brain : a journal of neurology
2017Other trialPMID 28334990DOIregistry reference BACKGROUND:28334990
R0022561Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D, Lancet (London, England)
2017Randomized trialPMID 28781108DOIregistry reference BACKGROUND:28781108
R0006628Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S, Diabetes, obesity & metabolism
2016Other trialPMID 26511102DOIregistry reference BACKGROUND:26511102
R0018908The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
Athauda D, Drug discovery today
2016Other trialPMID 26851597DOIregistry reference BACKGROUND:26851597
R0018159Potential side effects to GLP-1 agonists: understanding their safety and tolerability.
Consoli A, Expert opinion on drug safety
2015Nonrandomized studyPMID 25496749DOIregistry reference BACKGROUND:25496749
R0028198Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Cork SC, Molecular metabolism
2015PreclinicalPMID 26500843DOIregistry reference BACKGROUND:26500843
R0022385Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.
Greig NH, Alzheimer's & dementia : the journal of the Alzheimer's Association
2014OtherPMID 24529527DOIregistry reference BACKGROUND:24529527
R0026554Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Aviles-Olmos I, Journal of Parkinson's disease
2014Randomized trialPMID 24662192DOIregistry reference BACKGROUND:24662192
R0026610Exenatide and the treatment of patients with Parkinson's disease.
Aviles-Olmos I, The Journal of clinical investigation
2013Randomized trialPMID 23728174DOIregistry reference BACKGROUND:23728174
R0026474Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS, Diabetes, obesity & metabolism
2012OtherPMID 22236356DOIregistry reference BACKGROUND:22236356
R0027649DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T, The Journal of clinical endocrinology and metabolism
2011Randomized trialPMID 21307137DOIregistry reference BACKGROUND:21307137
R0020417Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Bergenstal RM, Lancet (London, England)
2010Randomized trialPMID 20580422DOIregistry reference BACKGROUND:20580422
R0025313Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Drucker DJ, Lancet (London, England)
2008Randomized trialPMID 18782641DOIregistry reference BACKGROUND:18782641